Rob O'Brien just returned from the Employers Health Pharmacy Benefit Conference, where biosimilars, state and federal regulations and paying for cell and gene therapies were all top of mind. Read on to hear what stuck with him.
read full article ›An interesting article from The Pink Sheet caught our eye. It analyzes the EUA for molnupiravir, Merck’s COVID-19 pill, which gained emergency use partly for its accessibility.
read full article ›Real Endpoints views the Prescription Digital Therapeutics Act of 2022 as a critical piece of legislation to help broaden appropriate access to prescription digital therapeutics (PDTs), an emerging therapeutic modality.
read full article ›On IWD22 day, we are excited to announce that Real Endpoints’ Susan Raiola will be moderating an all women panel at BIO featuring industry experts discussing patient-centered value based arrangements.
read full article ›Its déjà vu all over again…much like psoriasis, atopic derm is an increasingly crowded category where new entrants may hold some clinical differentiation, but in the ways that matter to payers, they all look exactly the same.
read full article ›For Rare Disease Day, please join Real Endpoints in raising awareness of individuals living with rare disease.
read full article ›As the Medicare Advantage plans continue to grow this will create new challenges for medical benefit (Part B) drugs – and how manufacturers navigate the differences of traditional Medicare vs. MA plans.
read full article ›We are looking forward to attending PCMA next week and connecting with colleagues, friends and partners. Are you heading to PCMA? Reach out and we can schedule time or look for us all around the conference and say hello! Safe travels and see you in Orlando!!
read full article ›Optum’s new tool, “Specialty Fusion,” is another example of vertically integrated payer unlocking specialty management across pharmacy and medical benefits. Manufacturers beware, solutions like Specialty Fusion will allow payers to leverage the dynamics of managing specialty across multiple benefits, including – competition across benefits to drive to low-net cost therapies, single PA tool, greater efficiency with real-time benefit information for the prescriber, and optimized site of service selection (helping the patient secure the lowest cost site of care).
read full article ›Headed to the Festival of Biologics this March? We hope you will join Real Endpoints President, Susan Raiola and other distinguished panel participants, as they discuss "Promoting Biosimilar Update"
read full article ›